Current therapy for Wilms' tumor

Oncologist

Volumn 10, Issue 10, 2005, Pages 815-826

  Metzger, Monika L ^a   Dome, Jeffrey S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Nephroblastoma; NWTS; Pediatric cancer; SIOP; Therapy; Wilms' tumor

Indexed keywords

BIOLOGICAL FACTOR; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; THIOTEPA; VINCRISTINE;

ANAPLASTIC CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHROMOSOME; CLINICAL PROTOCOL; CLINICAL TRIAL; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; NEPHROBLASTOMA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

HUMANS; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; WILMS TUMOR;

EID: 31444446505     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-10-815     Document Type: Review

References (109)

1. Willetts IE. Jessop and the Wilms' tumor. J Pediatr Surg 2003;38:1496-1498.
2. Wilms M. Die Mischgeschwülste der Niere. Georgi A, ed. Leipzig, Germany: 1899.
3. Kalapurakal JA, Dome JS, Perlman EJ et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol 2004;5:37-46.
4. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms' tumors: results from the First National Wilms' Tumor Study. Cancer 1978;41:1937-1948.
5. Faria P, Beckwith JB, Mishra K et al. Focal versus diffuse anaplasia in Wilms' tumor - new definitions with prognostic significance: a report from the National Wilms' Tumor Study Group. Am J Surg Pathol 1996;20:909-920.
6. Green DM, Beckwith JB, Breslow NE et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1994;12:2126-2131.
7. Green DM, Breslow NE, Beckwith JB et al. Treatment of children with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1994;12:2132-2137.
8. Haas JE, Palmer NF, Weinberg AG et al. Ultrastructure of malignant rhabdoid tumor of the kidney. A distinctive renal tumor of children. Hum Pathol 1981;12:646-657.
9. Haas JE, Bonadio JF, Beckwith JB. Clear cell sarcoma of the kidney with emphasis on ultrastructural studies. Cancer 1984;54:2978-2987.
10. Weeks DA, Beckwith JB, Mierau GW et al. Rhabdoid tumor of kidney. A report of 111 cases from the National Wilms' Tumor Study Pathology Center. Am J Surg Pathol 1989;13:439-458.
11. Beckwith JB. Wilms' tumor and other renal tumors of childhood: a selective review from the National Wilms' Tumor Study Pathology Center. Hum Pathol 1983;14:481-492.
12. de Kraker J, Graf N, van Tinteren H et al. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 2004;364:1229-1235.
13. Vujanic GM, Sandstedt B, Harms D et al. Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 2002;38:79-82.
14. Breslow N, Churchill G, Beckwith JB et al. Prognosis for Wilms' tumor patients with nonmetastatic disease at diagnosis - results of the second National Wilms' Tumor Study. J Clin Oncol 1985;3:521-531.
15. Breslow N, Sharples K, Beckwith JB et al. Prognostic factors in nonmetastatic, favorable histology Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1991;68:2345-2353.
16. Breslow NE, Palmer NF, Hill LR et al. Wilms' tumor: prognostic factors for patients without metastases at diagnosis: results of the National Wilms' Tumor Study. Cancer 1978;41:1577-1589.
17. Pritchard-Jones K, Kelsey A, Vujanic G et al. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilms' Tumor Working Group. J Clin Oncol 2003;21:3269-3275.
18. Green DM, Breslow NE, Beckwith JB et al. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study. J Clin Oncol 1993;11:91-95.
19. Green DM, Breslow NE, Beckwith JB et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2001;19:3719-3724.
20. Larsen E, Perez-Atayde A, Green DM et al. Surgery only for the treatment of patients with stage I (Cassady) Wilms' tumor. Cancer 1990;66:264-266.
21. Byrd RL, Evans AE, D'Angio GJ. Adult Wilms' tumor: effect of combined therapy on survival. J Urol 1982;127:648-651.
22. Arrigo S, Beckwith JB, Sharples K et al. Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 1990;66:827-830.
23. Reinhard H, Aliani S, Ruebe C et al. Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study. J Clin Oncol 2004;22:4500-4506.
24. Grundy P, Telzerow P, Moksness J et al. Clinicopathologic correlates of loss of heterozygosity in Wilms' tumor: a preliminary analysis. Med Pediatr Oncol 1996;27:429-433.
25. Grundy PE, Telzerow PE, Breslow N et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 1994;54:2331-2333.
26. Grundy RG, Pritchard J, Scambler P et al. Loss of heterozygosity on chromosome 16 in sporadic Wilms' tumour. Br J Cancer 1998;78:1181-1187.
27. Grundy PE, Breslow N, Li S et al. Loss of Heterozygosity for Chromosomes 1p and 16q is an Adverse Prognostic Factor in Favorable Histology Wilms' Tumor. A Report from the National Wilms' Tumor Study Group. J Clin Oncol 2005;23:7312-7321.
28. Hing S, Lu YJ, Summersgill B et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. Am J Pathol 2001;158:393-398.
29. Lu YJ, Hing S, Williams R et al. Chromosome 1q expression profiling and relapse in Wilms' tumour. Lancet 2002;360:385-386.
30. Dome JS, Bockhold CA, Li SM et al. High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms' tumor. J Clin Oncol 2005 Sept 19 (epub ahead of print).
31. Dome JS, Chung S, Bergemann T et al. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 1999;59:4301-4307.
32. Williams RD, Hing SN, Greer BT et al. Prognostic classification of relapsing favorable histology Wilms' tumor using cDNA microarray expression profiling and support vector machines. Genes Chromosomes Cancer 2004;41:65-79.
33. Li W, Kessler P, Yeger H et al. A gene expression signature for relapse of primary Wilms' tumors. Cancer Res 2005;65:2592-2601.
34. Takahashi M, Yang XJ, Lavery TT et al. Gene expression profiling of favorable histology Wilms' tumors and its correlation with clinical features. Cancer Res 2002;62:6598-6605.
35. D'Angio GJ. Pre- or post-operative treatment for Wilms' tumor? Who, what, when, where, how, why-and which. Med Pediatr Oncol 2003;41:545-549.
36. Ladd WE. Embryoma of the kidney (Wilms' tumor). Ann Surg 1938;108:885-902.
37. Shamberger RC, Guthrie KA, Ritchey ML et al. Surgery-related factors and local recurrence of Wilms' tumor in National Wilms' Tumor Study 4. Ann Surg 1999;229:292-297.
38. Ritchey ML, Shamberger RC, Haase G et al. Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group. J Am Coll Surg 2001;192:63-68.
39. Wilimas JA, Magill L, Parham DM et al. Is renal salvage feasible in unilateral Wilms' tumor? Proposed computed tomographic criteria and their relation to surgicopathologic findings. Am J Pediatr Hematol Oncol 1990;12:164-167.
40. Wilimas JA, Magill L, Parham DM et al. The potential for renal salvage in nonmetastatic unilateral Wilms' tumor. Am J Pediatr Hematol Oncol 1991;13:342-344.
41. Ritchey ML, Green DM, Thomas PR et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 1996;26:75-80.
42. Green DM, Jaffe N. The role of chemotherapy in the treatment of Wilms' tumor. Cancer 1979;44:52-57.
43. Green DM, Beckwith JB, Weeks DA et al. The relationship between microsubstaging variables, age at diagnosis, and tumor weight of children with stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor study. Cancer 1994;74:1817-1820.
44. Weeks DA, Beckwith JB, Luckey DW. Relapse-associated variables in stage I favorable histology Wilms' tumor. A report of the National Wilms' Tumor Study. Cancer 1987;60:1204-1212.
45. Shamberger RC. Pediatric renal tumors. Semin Surg Oncol 1999;16: 105-120.
46. Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA 1966;198:826-836.
47. Vietti TJ, Sullivan MP, Haggard ME et al. Vincristine sulfate and radiation therapy in metastatic Wilms' tumor. Cancer 1970;25:12-20.
48. D'Angio GJ, Evans A, Breslow N et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302-2311.
49. Green DM, Grigoriev YA, Nan B et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001;19:1926-1934.
50. Boccon-Gibod L, Rey A, Sandstedt B et al. Complete necrosis induced by preoperative chemotherapy in Wilms' tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9. Med Pediatr Oncol 2000;34:183-190.
51. Weirich A, Leuschner I, Harms D et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 2001;12:311-319.
52. Green DM, Breslow NE, Beckwith JB et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:3744-3751.
53. de Kraker J, Lemerle J, Voute PA et al. Wilms' tumor with pulmonary metastases at diagnosis: the significance of primary chemotherapy. International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee. J Clin Oncol 1990;8:1187-1190.
54. Pritchard J, Imeson J, Barnes J et al. Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. J Clin Oncol 1995;13:124-133.
55. Dome JS, Green DM, Cotton CA et al. Treatment of anaplastic Wilms' Tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 2005 (ASCO Annual Meeting Proceedings):8508.
56. Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms' tumor: a report from the National Wilms' Tumor Study Pathology Center. Hum Pathol 1988;19:1199-1209.
57. Montgomery BT, Kelalis PP, Blute ML et al. Extended follow-up of bilateral Wilms' tumor: results of the National Wilms' Tumor Study. J Urol 1991;146:514-518.
58. Horwitz JR, Ritchey ML, Moksness J et al. Renal salvage procedures in patients with synchronous bilateral Wilms' tumors: a report from the National Wilms' Tumor Study Group. J Pediatr Surg 1996;31:1020-1025.
59. Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. Philadelphia/Baltimore/New York/London/Buenos Aires/Hong Kong/Sydney/Tokyo: Lippincott Williams & Wilkins, 2001.
60. Bishop HC, Tefft M, Evans AE et al. Survival in bilateral Wilms' tumor - review of 30 National Wilms' Tumor Study cases. J Pediatr Surg 1977;12:631-638.
61. Blute ML, Kelalis PP, Offord KP et al. Bilateral Wilms' tumor. J Urol 1987;138:968-973.
62. Coppes MJ, de Kraker J, van Dijken PJ et al. Bilateral Wilms' tumor: long-term survival and some epidemiological features. J Clin Oncol 1989;7:310-315.
63. Jones B, Hrabovsky E, Kiviat N et al. Metachronous bilateral Wilms' tumor, National Wilms' Tumor Study. Am J Clin Oncol 1982;5:545-550.
64. Paulino AC, Thakkar B, Henderson WG. Metachronous bilateral Wilms' tumor: the importance of time interval to the development of a second tumor. Cancer 1998;82:415-420.
65. Coppes MJ, Arnold M, Beckwith JB et al. Factors affecting the risk of contralateral Wilms' tumor development: a report from the National Wilms' Tumor Study Group. Cancer 1999;85:1616-1625.
66. Groot-Loonen JJ, Pinkerton CR, Morris-Jones PH et al. How curable is relapsed Wilms' tumour? The United Kingdom Children's Cancer Study Group. Arch Dis Child 1990;65:968-970.
67. Grundy P, Breslow N, Green DM et al. Prognostic factors for children with recurrent Wilms' tumor: results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989;7:638-647.
68. Pinkerton CR, Groot-Loonen JJ, Morris-Jones PH et al. Response rates in relapsed Wilms' tumor. A need for new effective agents. Cancer 1991;67:567-571.
69. Wilimas JA, Champion J, Douglass EC et al. Relapsed Wilms' tumor. Factors affecting survival and cure. Am J Clin Oncol 1985;8:324-328.
70. Tournade MF, Lemerle J, Brunat-Mentigny M et al. Ifosfamide is an active drug in Wilms' tumor: a phase II study conducted by the French Society of Pediatric Oncology. J Clin Oncol 1988;6:793-796.
71. Abu-Ghosh AM, Krailo MD, Goldman SC et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report. Ann Oncol 2002;13:460-469.
72. de Camargo B, Melaragno R, Saba e Silva N et al. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol 1994;22:258-260.
73. Ettinger LJ, Gaynon PS, Krailo MD et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children's Cancer Group. Cancer 1994;73:1297-1301.
74. Kung FH, Desai SJ, Dickerman JD et al. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 1995;17:265-269.
75. Loss JF, Santos PP, Leone LD et al. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Pediatr Blood Cancer 2004;42:139-144.
76. Pein F, Pinkerton R, Tournade MF et al. Etoposide in relapsed or refractory Wilms' tumor: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 1993;11:1478-1481.
77. Pein F, Tournade MF, Zucker JM et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor - a phase II study by the French Society of Pediatric Oncology. J Clin Oncol 1994;12:931-936.
78. Pinkerton CR, Pritchard J. A phase II study of ifosfamide in paediatric solid tumours. Cancer Chemother Pharmacol 1989;24(suppl 1):S13-S15.
79. Pratt CB, Horowitz ME, Meyer WH et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131-135.
80. Pratt CB, Douglass EC, Etcubanas E et al. Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. Semin Oncol 1989;16:51-55.
81. Saylors RL III, Stewart CF, Zamboni WC et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:945-952.
82. Schwartzman E, Scopinaro M, Angueyra N. Phase II study of ifosfamide as a single drug for relapsed paediatric patients. Cancer Chemother Pharmacol 1989;24(suppl 1):S11-S12.
83. Tournade MF. A phase II study of ifosfamide in the treatment of relapses in Wilms' tumor. Cancer Chemother Pharmacol 1989;24(suppl 1):S31-S33.
84. Dome JS, Liu T, Krasin M et al. Improved survival for patients with recurrent Wilms' tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 2002;24:192-198.
85. Marina NM, Wilimas JA, Meyer WH et al. Refining therapeutic strategies for patients with resistant Wilms' tumor. Am J Pediatr Hematol Oncol 1994;16:296-300.
86. Green DM, Breslow NE, Ii Y et al. The role of surgical excision in the management of relapsed Wilms' tumor patients with pulmonary metastases: a report from the National Wilms' Tumor Study. J Pediatr Surg 1991;26:728-733.
87. Santana VM, Zamboni WC, Kirstein MN et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 2003;9:633-640.
88. Saylors RL III, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
89. Rowe DH, Kayton ML, O'Toole KM et al. Pathological angiogenesis in a murine model of human Wilms' tumor. J Pediatr Surg 1999;34:676-679.
90. Frischer JS, Huang J, Serur A et al. Effects of potent VEGF blockade on experimental Wilms' tumor and its persisting vasculature. Int J Oncol 2004;25:549-553.
91. Huang J, Frischer JS, Serur A et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-7790.
92. Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 2004;22:1366-1372.
93. Green DM, Breslow NE, Beckwith JB et al. Comparison between singledose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 1998;16:237-245.
94. Breslow NE, Ou SS, Beckwith JB et al. Doxorubicin for favorable histology, Stage II-III Wilms' tumor: results from the National Wilms' Tumor Studies. Cancer 2004;101:1072-1080.
95. Tournade MF, Com-Nougue C, de Kraker J et al. Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol 2001;19:488-500.
96. Mitchell C, Jones PM, Kelsey A et al. The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study. Br J Cancer 2000;83:602-608.
97. Sutow WW, Breslow NE, Palmer NF et al. Prognosis in children with Wilms' tumor metastases prior to or following primary treatment: results from the first National Wilms' Tumor Study (NWTS-1). Am J Clin Oncol 1982;5:339-347.
98. Green DM, Breslow NE, Evans I et al. The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms' tumor. A report from the National Wilms' Tumor Study. Am J Pediatr Hematol Oncol 1994;16:207-212.
99. Reinhard H, Semler O, Burger D et al. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms' Tumor. Klin Padiatr 2004;216:132-140.
100. Grundy RG, Hutton C, Middleton H et al. Outcome of patients with stage III or inoperable WT treated on the second United Kingdom WT protocol (UKWT2); a United Kingdom Children's Cancer Study Group (UKCCSG) study. Pediatr Blood Cancer 2004;42:311-319.
101. Burger D, Moorman-Voestermans CG, Mildenberger H et al. The advantages of preoperative therapy in Wilms' tumour. A summarised report on clinical trials conducted by the International Society of Paediatric Oncology (SIOP). Z Kinderchir 1985;40:170-175.
102. Lemerle J, Voute PA, Tournade MF et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.). Cancer 1976;38:647-654.
103. Lemerle J, Voute PA, Tournade MF et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol 1983;1:604-609.
104. Tournade MF, Com-Nougue C, Voute PA et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol 1993;11:1014-1023.
105. Garaventa A, Hartmann O, Bernard JL et al. Autologous bone marrow transplantation for pediatric Wilms' tumor: the experience of the European Bone Marrow Transplantation Solid Tumor Registry. Med Pediatr Oncol 1994;22:11-14.
106. Hempel L, Kremens B, Weirich A et al. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study. Klin Padiatr 1996;208:186-189.
107. Pein F, Michon J, Valteau-Couanet D et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998;16:3295-3301.
108. Kremens B, Gruhn B, Klingebiel T et al. High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma. Bone Marrow Transplant 2002;30:893-898.
109. Campbell AD, Cohn SL, Reynolds M et al. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital. J Clin Oncol 2004;22:2885-2890.